vs
Side-by-side financial comparison of NewAmsterdam Pharma Co N.V. (NAMS) and UNITED SECURITY BANCSHARES (UBFO). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $13.5M, roughly 1.4× UNITED SECURITY BANCSHARES). UNITED SECURITY BANCSHARES runs the higher net margin — 25.2% vs -90.7%, a 115.9% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs 13.6%). UNITED SECURITY BANCSHARES produced more free cash flow last quarter ($19.8M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
United Security Bancshares is a bank holding company headquartered in Fresno, California. It operates 11 branches.
NAMS vs UBFO — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $19.1M | $13.5M |
| Net Profit | $-17.4M | $3.4M |
| Gross Margin | — | — |
| Operating Margin | -186.1% | 31.5% |
| Net Margin | -90.7% | 25.2% |
| Revenue YoY | 740.1% | 13.6% |
| Net Profit YoY | 55.5% | 36.8% |
| EPS (diluted) | $-0.15 | $0.18 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $13.5M | ||
| Q3 25 | — | $14.0M | ||
| Q2 25 | $19.1M | $12.6M | ||
| Q1 25 | — | $13.7M | ||
| Q4 24 | $12.8M | $11.9M | ||
| Q3 24 | $29.1M | $13.8M | ||
| Q2 24 | — | $13.0M | ||
| Q1 24 | — | $12.8M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-17.4M | $2.2M | ||
| Q1 25 | — | $2.7M | ||
| Q4 24 | $-92.2M | $2.5M | ||
| Q3 24 | $-16.6M | $3.8M | ||
| Q2 24 | — | $4.3M | ||
| Q1 24 | — | $4.2M |
| Q4 25 | — | 31.5% | ||
| Q3 25 | — | 40.3% | ||
| Q2 25 | -186.1% | 24.0% | ||
| Q1 25 | — | 27.5% | ||
| Q4 24 | -338.5% | 27.5% | ||
| Q3 24 | -85.9% | 37.1% | ||
| Q2 24 | — | 46.4% | ||
| Q1 24 | — | 45.9% |
| Q4 25 | — | 25.2% | ||
| Q3 25 | — | 28.7% | ||
| Q2 25 | -90.7% | 17.2% | ||
| Q1 25 | — | 19.6% | ||
| Q4 24 | -721.7% | 20.9% | ||
| Q3 24 | -57.2% | 27.7% | ||
| Q2 24 | — | 33.0% | ||
| Q1 24 | — | 32.6% |
| Q4 25 | — | $0.18 | ||
| Q3 25 | — | $0.23 | ||
| Q2 25 | $-0.15 | $0.13 | ||
| Q1 25 | — | $0.16 | ||
| Q4 24 | $-0.91 | $0.14 | ||
| Q3 24 | $-0.18 | $0.22 | ||
| Q2 24 | — | $0.25 | ||
| Q1 24 | — | $0.24 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $739.2M | $264.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $778.5M | $139.7M |
| Total Assets | $815.1M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $264.2M | ||
| Q3 25 | — | $211.1M | ||
| Q2 25 | $739.2M | $199.5M | ||
| Q1 25 | — | $198.4M | ||
| Q4 24 | $834.2M | $216.9M | ||
| Q3 24 | $422.7M | $216.8M | ||
| Q2 24 | — | $166.3M | ||
| Q1 24 | — | $168.6M |
| Q4 25 | — | $139.7M | ||
| Q3 25 | — | $137.4M | ||
| Q2 25 | $778.5M | $134.3M | ||
| Q1 25 | — | $132.9M | ||
| Q4 24 | $757.5M | $130.4M | ||
| Q3 24 | $378.9M | $132.9M | ||
| Q2 24 | — | $127.3M | ||
| Q1 24 | — | $124.2M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | $815.1M | $1.2B | ||
| Q1 25 | — | $1.2B | ||
| Q4 24 | $864.6M | $1.2B | ||
| Q3 24 | $439.2M | $1.3B | ||
| Q2 24 | — | $1.2B | ||
| Q1 24 | — | $1.2B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-37.7M | $22.1M |
| Free Cash FlowOCF − Capex | $-37.8M | $19.8M |
| FCF MarginFCF / Revenue | -197.2% | 146.0% |
| Capex IntensityCapex / Revenue | 0.5% | 16.8% |
| Cash ConversionOCF / Net Profit | — | 6.46× |
| TTM Free Cash FlowTrailing 4 quarters | $-119.7M | $36.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $22.1M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | $-37.7M | $8.7M | ||
| Q1 25 | — | $3.0M | ||
| Q4 24 | $-37.5M | $19.6M | ||
| Q3 24 | $-12.5M | $5.4M | ||
| Q2 24 | — | $2.3M | ||
| Q1 24 | — | $7.4M |
| Q4 25 | — | $19.8M | ||
| Q3 25 | — | $6.1M | ||
| Q2 25 | $-37.8M | $8.1M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | $-37.5M | $18.6M | ||
| Q3 24 | $-12.6M | $5.3M | ||
| Q2 24 | — | $2.0M | ||
| Q1 24 | — | $7.0M |
| Q4 25 | — | 146.0% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | -197.2% | 64.3% | ||
| Q1 25 | — | 21.2% | ||
| Q4 24 | -293.5% | 156.0% | ||
| Q3 24 | -43.2% | 38.1% | ||
| Q2 24 | — | 15.5% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | — | 16.8% | ||
| Q3 25 | — | 6.0% | ||
| Q2 25 | 0.5% | 4.6% | ||
| Q1 25 | — | 0.9% | ||
| Q4 24 | 0.0% | 8.7% | ||
| Q3 24 | 0.3% | 0.7% | ||
| Q2 24 | — | 2.2% | ||
| Q1 24 | — | 3.6% |
| Q4 25 | — | 6.46× | ||
| Q3 25 | — | 1.73× | ||
| Q2 25 | — | 4.01× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 7.87× | ||
| Q3 24 | — | 1.40× | ||
| Q2 24 | — | 0.54× | ||
| Q1 24 | — | 1.79× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
